Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia : Effects on response and toxicity

Show full item record



Permalink

http://hdl.handle.net/10138/163541

Citation

Schiffer , C A , Cortes , J E , Hochhaus , A , Saglio , G , le Coutre , P , Porkka , K , Mustjoki , S , Mohamed , H & Shah , N P 2016 , ' Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia : Effects on response and toxicity ' , Cancer , vol. 122 , no. 9 , pp. 1398-1407 . https://doi.org/10.1002/cncr.29933

Title: Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia : Effects on response and toxicity
Author: Schiffer, Charles A.; Cortes, Jorge E.; Hochhaus, Andreas; Saglio, Giuseppe; le Coutre, Philipp; Porkka, Kimmo; Mustjoki, Satu; Mohamed, Hesham; Shah, Neil P.
Contributor: University of Helsinki, Clinicum
University of Helsinki, Satu Mustjoki / Principal Investigator
Date: 2016-05-01
Language: eng
Number of pages: 10
Belongs to series: Cancer
ISSN: 0008-543X
URI: http://hdl.handle.net/10138/163541
Abstract: BACKGROUNDThe proliferation of clonal cytotoxic T-cells or natural killer cells has been observed after dasatinib treatment in small studies of patients with chronic myeloid leukemia (CML). METHODSThe incidence of lymphocytosis and its association with response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib-treated patients with newly diagnosed CML in chronic phase (CML-CP), CML-CP refractory/intolerant to imatinib, or with CML in accelerated or myeloid-blast phase were analyzed. RESULTSLymphocytosis developed in 32% to 35% of patients and persisted for >12 months. This was not observed in the patients who received treatment with imatinib. Dasatinib-treated patients in all stages of CML who developed lymphocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML-CP with lymphocytosis were more likely to achieve major and deep molecular responses. Progression-free and overall survival rates were significantly longer in patients with CML-CP who were refractory to or intolerant of imatinib and had lymphocytosis. Pleural effusions developed more commonly in patients with lymphocytosis. CONCLUSIONSOverall, lymphocytosis occurred and persisted in many dasatinib-treated patients in all phases of CML. Its presence was associated with higher response rates, significantly longer response durations, and increased overall survival, suggesting an immunomodulatory effect. Prospective studies are warranted to characterize the functional activity of these cells and to assess whether an immunologic effect against CML is detectable. Cancer 2016;122:1398-1407. (c) 2016 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. Lymphocytosis develops frequently after treatment of chronic myeloid leukemia with dasatinib and is associated with higher response rates, significantly longer response durations, and increased overall survival. Prospective studies are warranted to assess whether dasatinib produces an immunomodulatory effect against chronic myeloid leukemia.
Subject: dasatinib
leukemia
chronic myeloid
killer cells
natural
lymphocytosis
T-lymphocytes
TYROSINE KINASE INHIBITOR
SRC FAMILY KINASES
CHRONIC-PHASE
T-CELLS
THERAPY
IMATINIB
PROLIFERATION
INTOLERANT
MUTATIONS
RESISTANT
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Lymphocytosis_After_Treatment.pdf 526.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record